Using PET Response Criteria in Solid Tumors (PERCIST) in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer

Study Overview
=================
Brief Summary
-----------------
This study is aimed to evaluate the effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients. Purpose: The incremental staging information by using 18F-FDG PET The impact of the PET results on the patients' subsequent therapy planning To compare treatment response using RECIST criteria and FDG PET results.

Detailed Description
-----------------
Background: Esophageal cancer is one of the leading malignancies in Taiwan. Accuracy tumor staging can direct to appropriate therapy planning and provide prognostic implications. Positron emission tomography (PET) with [18F]-fluoro-2-deoxy-D-glucose (FDG) has been shown to have better N staging and prognostic stratification abilities than conventional imaging modalities, such as endoscopic ultrasonography (EUS) and CT. Purpose: This study is aimed to evaluate the effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients. Method: Patients with pathological proven esophageal cancer, age 20-90 year-old, will be included in this study. Each patient will receive a baseline PET study. For those patients who received pre-operative CCRT, another PET will be performed 1-4 weeks after completion of CCRT. Primary outcome: 1. The incremental staging information by using 18F-FDG PET 2. The impact of the PET results on the patients' subsequent therapy planning 3. To compare treatment response using RECIST criteria and FDG PET results. Secondary outcome: To correlate the PET response rate and the patients' disease free survival and overall survival.

Official Title
-----------------
Using PET Response Criteria in Solid Tumors (PERCIST) in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer

Conditions
-----------------
Esophageal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age：20-90 years old Histological proved esophageal cancer ECOG performance status 0-2 written informed consent signed Exclusion Criteria: prior chemotherapy or treatment for other systemic anti-cancer agent(s) pregnant or intend to be pregnant other malignancies known other concurrent cancer treatment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| esophageal cancer, 18F-FDG PET<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients. |  | 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Esophageal cancer, 18F-FDG PET, staging, therapy planning, therapy response monitoring, prognosis